The Director General of the Jordanian Food and Drug Administration (JFDA), Nizar Muhaidat explained that the AstraZeneca vaccine has proven its efficacy in reducing hospital admissions and deaths resulting from COVID-19.

In a statement, Muhaidat stressed that the decision for Jordan to continue using the vaccine came based on recommendations from all drug authorities such as the European Medicines Agency.

Muhaidat added that several countries announced the resumption of using the AstraZeneca vaccine such as Britain, Australia, Italy, France, Spain, Portugal, as the risk of getting blood clots after receiving the vaccine did not exceed 0.0000015 percent.

No unexpected side effects have been reported to the JFDA from those who have taken the vaccine in Jordan.

Feb. 9, the JFDA approved the COVID-19 AstraZeneca vaccine for emergency use.

Also Read: Jordanian FDA to release statement on AstraZeneca vaccine